The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

The decision to terminate the HYPERION trial reflects a loss of clinical equipoise, making it unethical to continue the placebo-controlled study.

In addition to STELLAR, MSD is running the phase 3 HYPERION trial of sotatercept in newly diagnosed intermediate- and high-risk PAH patients, seeking to move it up the treatment pathway ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...

Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...

At the American College of Cardiology (ACC) meeting this week, Merck showcased two components of its cardiovascular pipeline – sotatercept for pulmonary arterial hypertension (PAH) and oral ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

which also goes by the name sotatercept, was originally picked up via Merck’s $11.5 billion acquisition of Acceleron back in 2021. The U.K.’s Medicines and Healthcare products Regulatory ...

Brad Smith breaks down the top headlines on today's Market Minute as US stocks (^DJI,^GSPC, ^IXIC) seemingly shake off tariff worries. Estée Lauder (EL) shares plunge after issuing weaker-than ...